Adverse events: Specific ‐ prolactin‐related · patients with schizophrenia
It is very uncertain whether RISPERIDONE DEPOT changes adverse events: Specific ‐ prolactin‐related compared with ORAL ARIPIPRAZOLE (very low certainty).
1 finding from 1 review
Relapse · patients with schizophrenia
1 finding from 1 review
Clinical response: mean score/change in mental state: mean PANSS total score (high = poor) · patients with schizophrenia
1 finding from 1 review
Leaving the study early · patients with schizophrenia
RISPERIDONE DEPOT may leads to higher leaving the study early: Any reason ‐ long term compared with ORAL OLANZAPINE (low certainty).
1 finding from 1 review
Adverse events: General ‐ serious · patients with schizophrenia
RISPERIDONE DEPOT showed no clear difference in adverse events: General ‐ serious compared with ORAL OLANZAPINE (low certainty).
1 finding from 1 review
Adverse effects: any observed extrapyramidal symptoms ‐ short term (up to 6 months) · patients with schizophrenia
RISPERIDONE DEPOT may leads to higher adverse events: Movement disorder ‐ any extra pyramidal symptoms compared with ORAL OLANZAPINE (low certainty).
1 finding from 1 review
Weight gain · patients with schizophrenia
RISPERIDONE DEPOT may leads to lower adverse events: Specific ‐ weight increase compared with ORAL OLANZAPINE (low certainty).
1 finding from 1 review
Relapse · patients with schizophrenia
It is very uncertain whether RISPERIDONE DEPOT changes global state: Relapse (any reason) ‐ long term Number of… compared with GENERAL ORAL ANTIPSYCHOTICS (very low certainty).
1 finding from 1 review
Mental state ‐ improvement · patients with schizophrenia
1 finding from 1 review
Leaving the study early · patients with schizophrenia
RISPERIDONE DEPOT showed no clear difference in leaving the study early: Any reason ‐ long term compared with GENERAL ORAL ANTIPSYCHOTICS (moderate certainty).
1 finding from 1 review
Adverse events: General: Severe adverse event ‐ any dose risperidone depot ‐ short term · patients with schizophrenia
1 finding from 1 review
Technical success · 52 people with TASC‐II D superficial femoral artery chronic total occlusions
OUTBACK re‐entry catheter showed no clear difference in technical success rate compared with manual re‐entry (low certainty).
1 finding from 1 review
months' patency rate · 52 people with TASC‐II D superficial femoral artery chronic total occlusions
OUTBACK re‐entry catheter showed no clear difference in months' patency rate compared with manual re‐entry (low certainty).
2 findings from 1 review
Primary patency ( · 52 people with TASC‐II D superficial femoral artery chronic total occlusions
2 findings from 1 review
Limb salvage · 52 people with TASC‐II D superficial femoral artery chronic total occlusions
1 finding from 1 review
Complications · 52 people with TASC‐II D superficial femoral artery chronic total occlusions
1 finding from 1 review
Clinical improvement · 52 people with TASC‐II D superficial femoral artery chronic total occlusions
1 finding from 1 review
Duration of crying (seconds) · Infants 1 to 12 months during vaccination
1 finding from 1 review
All pain scores during injection Due to range of pain scores used, data analysed using SMDs. Pain scores were measured during and up to 3 minutes following completion of vaccination. · Infants 1 to 12 months during vaccination
2 findings from 1 review
Heart rate · Infants 1 to 12 months during vaccination
1 finding from 1 review